Literature DB >> 12763624

Actions of oxytocin and interactions with glutamate on spontaneous and evoked dorsal spinal cord neuronal activities.

Miguel Condés-Lara1, Nephtali Marina González, Guadalupe Martínez-Lorenzana, Oliva Luis Delgado, Marie José Freund-Mercier.   

Abstract

Among the numerous pain control mechanisms that have been proposed, those acting at the spinal cord have been broadly studied, but little is known about how neuropeptides originating in supraspinal structures may relate to pain and analgesic mechanisms. Oxytocin (OT), in addition to its well known hormonal action, produces neuronal effects in various regions of the central nervous system. Indeed, some parvocellular neurons in the hypothalamic paraventricular nucleus (PVN) are oxytocinergic and project to the caudal part of the brain and the spinal cord. Moreover, the rat spinal cord shows a good overlap between the oxytocinergic hypothalamo-spinal neuron projections and the distribution of OT binding sites. However, the physiological significance of these binding sites is largely unknown. Extracellular unit activity of spinal cord neurons was recorded at the T13-L1 levels in male rats anesthetized with halotane. Somatic stimulation was applied to the inner and outer thigh of the ipsilateral hindpaw, and glutamate (GLU) and OT were locally delivered by pressure using pipettes coupled to recording electrodes. Our results show that spinal cord neurons, mainly located in the dorsal horn, in the intermediolateral cell column (IML) and in the intermediomedial gray matter (IMM), respond to the application of OT (71.5%) with activation (48%) or inhibition (52%). In some cases, opposite OT effects were observed during simultaneous recordings of two cells, suggesting OT activation of an inhibitory interneuron followed by the inhibition of the second recorded neuron. Increases in neuronal firing rate produced by GLU could be blocked by prior OT application. Finally, OT could reduce or partially block the responses to tactile and nociceptive somatic stimulation. We found that spinal cord neurons are sensitive to OT indicating that OT binding sites are functionally active. OT effects suggest the activation of inhibitory interneurons acting on a second order projecting cells to modulate afferent tactile and nociceptive information.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763624     DOI: 10.1016/s0006-8993(03)02690-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  Oxytocin - a multifunctional analgesic for chronic deep tissue pain.

Authors:  Burel R Goodin; Timothy J Ness; Meredith T Robbins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Intrathecal oxytocin inhibits visceromotor reflex and spinal neuronal responses to noxious distention of the rat urinary bladder.

Authors:  Mitchell P Engle; Timothy J Ness; Meredith T Robbins
Journal:  Reg Anesth Pain Med       Date:  2012 Sep-Oct       Impact factor: 6.288

3.  Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse.

Authors:  Ara Schorscher-Petcu; Susana Sotocinal; Sorana Ciura; Anouk Dupré; Jennifer Ritchie; Robert E Sorge; Jacqueline N Crawley; Shuang-Bao Hu; Katsuhiko Nishimori; Larry J Young; Eliane Tribollet; Rémi Quirion; Jeffrey S Mogil
Journal:  J Neurosci       Date:  2010-06-16       Impact factor: 6.167

Review 4.  REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy.

Authors:  Cedric Viero; Izumi Shibuya; Naoki Kitamura; Alexei Verkhratsky; Hiroaki Fujihara; Akiko Katoh; Yoichi Ueta; Hans H Zingg; Alexandr Chvatal; Eva Sykova; Govindan Dayanithi
Journal:  CNS Neurosci Ther       Date:  2010-07-07       Impact factor: 5.243

5.  A New Population of Parvocellular Oxytocin Neurons Controlling Magnocellular Neuron Activity and Inflammatory Pain Processing.

Authors:  Marina Eliava; Meggane Melchior; H Sophie Knobloch-Bollmann; Jérôme Wahis; Miriam da Silva Gouveia; Yan Tang; Alexandru Cristian Ciobanu; Rodrigo Triana Del Rio; Lena C Roth; Ferdinand Althammer; Virginie Chavant; Yannick Goumon; Tim Gruber; Nathalie Petit-Demoulière; Marta Busnelli; Bice Chini; Linette L Tan; Mariela Mitre; Robert C Froemke; Moses V Chao; Günter Giese; Rolf Sprengel; Rohini Kuner; Pierrick Poisbeau; Peter H Seeburg; Ron Stoop; Alexandre Charlet; Valery Grinevich
Journal:  Neuron       Date:  2016-03-03       Impact factor: 17.173

6.  Intracisternal injection of palmitoylethanolamide inhibits the peripheral nociceptive evoked responses of dorsal horn wide dynamic range neurons.

Authors:  Abimael González-Hernández; Guadalupe Martínez-Lorenzana; Javier Rodríguez-Jiménez; Gerardo Rojas-Piloni; Miguel Condés-Lara
Journal:  J Neural Transm (Vienna)       Date:  2014-06-12       Impact factor: 3.575

7.  Recurrent antinociception induced by intrathecal or peripheral oxytocin in a neuropathic pain rat model.

Authors:  Abimael González-Hernández; Antonio Espinosa De Los Monteros-Zuñiga; Guadalupe Martínez-Lorenzana; Miguel Condés-Lara
Journal:  Exp Brain Res       Date:  2019-09-12       Impact factor: 1.972

8.  Oxytocin inhibits hindpaw hyperalgesia induced by orofacial inflammation combined with stress.

Authors:  Yue-Xin Li; Jia-Heng Li; Yi Guo; Zhuo-Ying Tao; Shi-Hao Qin; Richard J Traub; Hong An; Dong-Yuan Cao
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.370

9.  Nanomolar oxytocin synergizes with weak electrical afferent stimulation to activate the locomotor CpG of the rat spinal cord in vitro.

Authors:  Francesco Dose; Patrizia Zanon; Tamara Coslovich; Giuliano Taccola
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

10.  Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition.

Authors:  Jean-Didier Breton; Pierre Veinante; Sandra Uhl-Bronner; Angela Maria Vergnano; Marie José Freund-Mercier; Rémy Schlichter; Pierrick Poisbeau
Journal:  Mol Pain       Date:  2008-05-29       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.